In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopharma Dealmaking Quarterly Statistics, Q3 2013

A look at the financing, M&A, and alliance activity July-September 2013

Executive Summary

Biopharma financing in Q3 2013 totaled $4.6 billion, a 58% drop from the second quarter; Perrigo’s $8.3 billion acquisition of Elan made up more than half of the M&A dollar value; and marketed products made up the majority of licensed products.

Advertisement

Related Content

Isis Builds On Platform Strategy With Fourth Biogen Tie-Up
KV Emerging From Bankruptcy As Makena Sales Pick Up Steam
Astex Finds A Suitable Home As Otsuka Subsidiary
Ophthalmology M&A Engine Keeps Roaring As Akorn Buys Out Hi-Tech
MedImmune To Enhance Oncology Pipeline With Buyout Of Neighbor Amplimmune
Next Up For Cubist: A Future That Includes Optimer, Trius
Royalty Pharma Earns Its Profits The Slow Way
Elan’s Saga Comes To A Close With Perrigo’s $8.6 Billion Bid
AstraZeneca’s “Smart Risks” Include Sharing FibroGen’s Anemia Compound With Astellas
Double-Jointed Partnership With Servier Could Jumpstart Amgen’s CV Portfolio

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003965

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel